Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling(Ludwig-Maximilians-Universität München), Mats Jerkeman(Skåne University Hospital), Simon Rule(AstraZeneca (United Kingdom)), Sanne H. Tonino(Amsterdam UMC Location University of Amsterdam), Marco Ladetto(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), John F. Seymour(The Royal Melbourne Hospital), Gilles Salles(Memorial Sloan Kettering Cancer Center), Klaus Herfarth(Heidelberg University), Michele Ghielmini(Institute of Oncology Research)
Cited by 267
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920